APPLICATIONS FOR WOUND CARE
Tissue engineering and regenerative medicine techniques leverage amniotic membrane patches and connective tissue supplements to create substitutes that help accelerate wound closure.
Contact Us
The Role Regenerative Medicine Plays in Complex Wound Care
One of regenerative medicine’s primary objectives is to offer innovative options addressing complex wounds that are not responding to conventional methods. Tissue engineering and regenerative medicine techniques focus on creating substitutes using amniotic membrane patches alongside connective tissue supplements to expedite wound closure.
AmnioText in Wound Care
The dual-layer patch, AmnioText™ , is a sterile, dehydrated human amniotic membrane allograft, intended for homologous use to cover and protect the recipient’s tissues. AmnioText™ is minimally manipulated and processed to preserve the original relevant characteristics relating to its utility as a barrier.Explore applications of amniotic membrane allografts in advanced, chronic cases and view the associated research:
The patient’s body can use the collagenic superstructure from the newly transplanted Wharton’s jelly as building blocks to fill voids or defects in soft tissues. Successfully pinpointing and addressing the underlying cause rather than just managing symptoms can provide patients with a chance for sustained enhancement in the wound closure process, leading to an improved quality of life.
CryoText™ in Wound Care
CryoText™ is our most concentrated, non-coded Wharton’s jelly or human umbilical cord product is rich in cytokines, growth factors, and scaffolding proteins. It is used as a replacement tissue intended to replace missing or damaged connective tissue. Explore applications of Wharton’s jelly allografts in advanced, chronic cases and view the associated research:
Regenative Labs’ resources are divided into the following categories:
Discover
Discover our catalogue of applications showcasing how Regenative Labs’ proprietary products can be used.
View all Applications
STUDY
Study the latest innovations and the variety of options available to medical specialties.
View Publications
EXPLORE
Explore the detailed descriptions of our products, their make-up and development through our state-of-the-art process and to identify which products are best suited for your patients’ unique needs.
VIEW ALL PRODUCTSCommitment to Quality and Transparency
Regenative Labs is a leader in the field of regenerative medicine. Our commitment to quality and transparency is demonstrated by collecting data from patient outcomes and analyzing it for statistical significance, ensuring physicians make the most informed decision to facilitate the best possible outcomes for their patients.
Our shared goal is to address the root cause of the problem for patients in debilitating situations and partner to offer an effective and minimally-invasive option.
You know the vital role tissue health plays in the overall well-being of patients. Regenative Labs’ mission is to facilitate predictable patient outcomes by offering the highest quality human tissue allografts available.
Contact Us
LEARN About Wharton’s Jelly
About Wharton’s Jelly
Wharton’s Jelly (WJ) was initially characterized in 1656 by Thomas Wharton[1]. Advances in regenerative medicine have increased significantly throughout the past decade. Located between the blood vessels of the umbilical cord and the amniotic epithelium, WJ spans the entire length of the umbilical cord, providing protection, cushioning, and structural support [2,3].
read research articleADVANTAGES OF WHARTON’S JELLY
This connective tissue contains high amounts of extracellular matrix components including collagen types I, III, and V, elastin, and fibronectin [1, 2]. Wharton’s jelly mainly provides cushioning and structural support to the umbilical cord but also contains a natural source of long-chain hyaluronic acid and numerous cytokines and growth factors. Studies have described placental tissues to be “immune privileged” as they rarely evoke an immune response in the body, reducing the risk of adverse reactions [4].
CITATIONS:
1. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jelly derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390/ijms140611692. PMID: 23727936; PMCID: PMC3709752.
2. Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020 Feb 13;15(1):49. doi: 10.1186/s13018-020-1553-7. PMID: 32054483; PMCID: PMC7017504.
3. Deus IA, Mano JF, Custódio CA. Perinatal tissues and cells in tissue engineering and regenerative medicine. Acta Biomater. 2020 Jul 1;110:1-14. doi: 10.1016/j. actbio.2020.04.035. Epub 2020 May 14. PMID: 32418650.
4. Jadalannagari S, Converse G, McFall C, Buse E, Filla M, Villar MT, Artigues A, MellotAJ, Wang J, Detamore MS, Hopkins RA, Aljitawi OS. Decellularized Wharton’s Jelly from human umbilical cord as a novel 3D scaffolding material for tissue engineering applications. PLoS One. 2017 Feb 21;12(2):e0172098. doi: 10.1371/journal. pone.0172098. Erratum in: PLoS One. 2017 Mar 7;12 (3):e0173827. PMID: 28222169; PMCID: PMC5319682.
CryoText™ Product Information
For more information about our Cryotext™ product, visit the link below.
Pricing and PLACING AN order
For pricing or to place an order, login or setup an account to get immediate access to our MEDNGINE platform.
DON’t HESITATE TO REACH OUT.
If you have any further questions, please contact us. We look forward to speaking with you!